Key facts
- This page summarizes Gotham Makker's Form 4 filing for ROCKET PHARMACEUTICALS, INC. (RCKT).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 29 Oct 2024, 16:58.
Gotham Makker - 26 Sep 2024 Form 4 Insider Report for ROCKET PHARMACEUTICALS, INC. (RCKT)
- Reporting relationship
- Director
- Issuer ticker
- RCKT
- Reported as of
- 26 Sep 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 29 Oct 2024, 16:58:22 UTC
- Prior SEC filing
- 20 Jun 2024
- Next SEC filing
- 18 Jul 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Martin Wilson, as attorney-in-fact for Gotham Makker
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Gotham Makker filed Form 4 for ROCKET PHARMACEUTICALS, INC. (RCKT) on 29 Oct 2024.
Change
- Previous filing in this sequence was filed on 20 Jun 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
RCKT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +204
- Change %
- Price
- $0.000000
- Shares after
- 204
- Date
- 26 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 204
- Exercise price
- $17.60
- Footnotes
- F1
RCKT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +303
- Change %
- Price
- $0.000000
- Shares after
- 303
- Date
- 26 Sep 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 303
- Exercise price
- $17.60
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
This option represents a right to purchase a total of 204 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on September 26, 2025.
Footnote F2
This option represents a right to purchase a total of 303 shares of the Issuer's Common Stock, all of which will become fully vested and exercisable on September 26, 2025.